BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11269881)

  • 1. [Usefulness of RET proto-oncogene in the diagnosis of hereditary-type medullary carcinoma of the thyroid. Correlation with surgical findings].
    Carreño M; Girbés J; Malluguiza R; Serrano S; Matias-Guiu X; Tudela J; Alfayate R; Lagarda H
    Acta Otorrinolaringol Esp; 2001; 52(1):57-63. PubMed ID: 11269881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
    Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
    Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
    Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M
    Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G; Domené HM; Iorcansky S; Barontini M
    Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma.
    Miyauchi A; Matsuzuka F; Hirai K; Yokozawa T; Kobayashi K; Kuma S; Kuma K; Futami H; Yamaguchi K
    World J Surg; 2000 Nov; 24(11):1367-72. PubMed ID: 11038208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
    Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.
    Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ
    Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M; Jackson CE; Feldman GL
    Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
    Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M; Weinhüsel A; Niederle B; Haas OA
    Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
    Frilling A; Dralle H; Eng C; Raue F; Broelsch CE
    Surgery; 1995 Dec; 118(6):1099-103; discussion 1103-4. PubMed ID: 7491529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ; Mulligan LM; Eng C
    Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ret proto-oncogene mutation found in the Czech population and its predictive value for offspring of patients with medullary carcinoma of the thyroid gland].
    Mazura I; Vcelák J; Bendlová B; Neradilová M; Nĕmec J; Stolba P
    Vnitr Lek; 1996 Nov; 42(11):751-6. PubMed ID: 9012117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy.
    Siggelkow H; Melzer A; Nolte W; Karsten K; Hoppner W; Hufner M
    Eur J Endocrinol; 2001 May; 144(5):467-73. PubMed ID: 11331212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ret-proto-oncogene analysis in medullary thyroid carcinoma.
    O'Keeffe DA; Hill AD; Sheahan K; Ryan F; Barton D; Fitzgerald RJ; McDermott EW; O'Higgins NJ
    Ir J Med Sci; 1998; 167(4):226-30. PubMed ID: 9868860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation.
    Feldman GL; Edmonds MW; Ainsworth PJ; Schuffenecker I; Lenoir GM; Saxe AW; Talpos GB; Roberson J; Petrucelli N; Jackson CE
    Surgery; 2000 Jul; 128(1):93-8. PubMed ID: 10876191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presymptomatic genetic screening in families with multiple endocrine neoplasia type 2.
    Frilling A; Höppner W; Eng C; Mulligan L; Raue F; Broelsch CE
    J Mol Med (Berl); 1995 May; 73(5):229-33. PubMed ID: 7670926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genetic testing for ret mutation for early diagnosis and treatment in familial medullary thyroid carcinoma: a case report].
    Nagaoka H; Iino Y; Takei H; Maemura M; Horiguchi J; Horii Y; Matumoto H; Koibuchi Y; Ninomiya J; Yokoe T; Oyama T; Morishita Y
    Gan To Kagaku Ryoho; 1998 Apr; 25 Suppl 3():481-5. PubMed ID: 9589057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
    Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
    Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
    J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.